Eli Lilly's Zepbound and Mounjaro are no longer in shortage. Here's where their sales still disappointed

• Lilly’s Mounjaro, Zepbound drugs see strong demand. So why did sales disappoint?

  Business - MarketWatch - 2 hours ago
• 

  Shares in weight-loss drugmaker Eli Lilly fall on disappointing sales

  Business - Financial Times - 9 hours ago

• Eli Lilly to trial use of weight loss drugs to combat unemployment in UK

  Business - CNBC - October 15
• 

  Eli Lilly to trial use of weight loss drugs to combat unemployment in U.K.

  Top stories - NBC News - October 16

More from CNBC

• Meta misses on user growth, warns of 2025 jump in AI spending

  Business - CNBC - 7 minutes ago

• Microsoft beats on top and bottom lines, driven by better-than-expected cloud growth

  Business - CNBC - 22 minutes ago

• Starbucks CEO pledges to fundamentally change strategy as sales fall for third straight quarter

  Business - CNBC - 47 minutes ago

• Carvana raises 2024 earnings guidance after topping Wall Street's Q3 expectations

  Business - CNBC - 40 minutes ago

• Coinbase shares tumble as muted crypto trading leads to a third-quarter miss

  Business - CNBC - 21 minutes ago